Banque Cantonale Vaudoise’s Intellia Therapeutics NTLA Stock Holding History

Banque Cantonale Vaudoise’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-415	Closed	-$21K	–	1268
2022 Q2	$21K	Hold	415	–	–	﹤0.01%	1127
2022 Q1	$30K	Hold	415	–	–	﹤0.01%	1116
2021 Q4	$49K	Hold	415	–	–	﹤0.01%	1075
2021 Q3	$56K	Buy	+415	New	+$62.8K	﹤0.01%	1032
2021 Q1	–	Sell	-700	Closed	-$47K	–	1178
2020 Q4	$38K	Hold	700	–	–	﹤0.01%	970
2020 Q3	$14K	Buy	+700	New	+$14.6K	﹤0.01%	995

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Banque Cantonale Vaudoise's NTLA Position: Q3 2022 in Review

Banque Cantonale Vaudoise sold out of Intellia Therapeutics (NTLA) in Q3 2022, closing a stake of 415 shares — an estimated $21K sold.

Banque Cantonale Vaudoise first reported a position in NTLA in Q3 2020 and held it in 6 quarters. The position peaked at $56K in Q3 2021. 319 funds tracked by Wall St. Rank hold NTLA as of Q3 2022.

Banque Cantonale Vaudoise reported no remaining Intellia Therapeutics position as of Q3 2022 after selling out during the quarter.
Banque Cantonale Vaudoise sold 415 Intellia Therapeutics shares in Q3 2022, an estimated $21K.
Banque Cantonale Vaudoise first reported a position in Intellia Therapeutics in Q3 2020 and held it in 6 quarters.
Banque Cantonale Vaudoise's Intellia Therapeutics position peaked at $56K in Q3 2021.
319 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2022.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2022, filed 17 Oct 2022.